Developer docs
API playgroundTry for free, no card

Search company profiles

ApconiX

Full company profile

uuid000uytm

Namestring
ApconiX
Legal namestring
ApconiX Ltd.
Websiteurl
apconix.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

ApconiX is a privately-held, UK-based nonclinical drug safety consultancy founded in July 2015 by Prof Ruth Roberts, Dr Richard Knight and Dr Michael Morton in the wake of AstraZeneca's closure of its Alderley Park R&D site. The firm is headquartered at Alderley Park (Cheshire) and operates a wholly-owned Swedish subsidiary, ApconiX AB, at the BioVentureHub in Gothenburg; it employs more than 100 scientists and markets over 500 years of combined drug discovery and development experience across all major safety disciplines.

The company is organised around three service pillars. Toxicology and DMPK Consultancy covers drug project toxicology, drug metabolism and pharmacokinetics, study monitoring, due diligence, inhalation toxicology, genetic and reproductive toxicology, safety and secondary pharmacology, immunotoxicology, medical device biocompatibility, and OEL/PDE calculations. Ion Channel Screening is delivered from the firm's own laboratory and includes cardiac safety assays (hERG and full CiPA panels on QPatch II, Patchliner, and Axion BioSystems Maestro Pro platforms), the proprietary iSLA in vitro Seizure Liability Assay, and in silico cardiac safety modelling aligned with ICH E14/S7B Q&A. Safety Science encompasses Acuity AI-supported Target Safety Assessments, weight-of-evidence evaluations, and data science services spanning predictive toxicology, chemoinformatics, and safety informatics.

ApconiX generates revenue through quote-based, project- and retainer-style professional services engagements ranging from short consulting hours to multi-year programme support. Customers are primarily small-to-mid-size biotechnology and large biopharmaceutical companies, with academia as a secondary segment, served through direct sales and CRO alliance channels; 60% of work is delivered to clients outside the UK across more than 30 countries. Named customers include Gilead Sciences, Sanofi and Bugworks Research, and the firm has received the Queen's Award for Enterprise for International Trade (2022), the King's Award for Enterprise for International Trade, and the King's Award for Enterprise for Innovation (2025), among other recognitions.

Short descriptiontext

ApconiX is a UK-based nonclinical drug safety consultancy, founded in 2015, that delivers toxicology, DMPK, ion channel screening, and AI-supported target safety assessment services to biotech, biopharma, and academic clients across more than 30 countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersMacclesfield, United Kingdom
HQ citystring
Macclesfield
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
drug safety consulting, nonclinical toxicology services, ion channel screening, target safety assessment, DMPK consultancy
Industry4 codes
PRIMARYHLAGAAAC
Toxicology & Safety Assessment CROs (GLP)
SECONDARYHLAGAFAB
Safety Pharmacology (Cardio/CNS/Respiratory)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGAFAN
Nonclinical Study Management & Regulatory Writing (IND-enabling)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
NAICS code2 codes
  • Testing Laboratories and Services54138
  • Other Scientific and Technical Consulting Services541690
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Testing Laboratories8734
Product category
Nonclinical Drug Safety Consulting
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Toxicology and DMPK Consultancy
TypeProfessional Services
Description

Flexible consulting services providing access to experienced nonclinical safety scientists for drug discovery and development projects. Services include study design, CRO selection, study monitoring, regulatory document authoring, and expert toxicology advice. Works with discovery and development teams from project initiation through to worldwide marketing approval.

apconix.com
2Ion Channel Screening Services
TypeProfessional Services
Description

Laboratory services for cardiac and CNS ion channel screening including hERG screening, CiPA assays, and seizure liability assessment. Turnaround times of 4 days for hERG and 14 days for CiPA screening.

apconix.com
3Safety Science and Target Safety Assessments
TypeProfessional Services
Description

Acuity TSAs combining AI technology with expert toxicologist interpretation, Weight of Evidence assessments, and data science services for biodata analysis and predictive toxicology.

apconix.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details1 tier
1Professional consultancy services
ModelOtherBilling cadenceMulti-year contract
Notes

Quote-based / Not publicly disclosed. Services are tailored to client needs from brief consultations to multi-year support.

apconix.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1Acuity Target Safety Assessments (TSAs)
Description

AI-assisted target safety assessment products combining public domain information with expert toxicologist interpretation to identify key risks by organ/tissue.

apconix.com
+2 more records
Core offering1 text field

ApconiX provides expert nonclinical drug safety consultancy and laboratory-based ion channel screening services to biotech, biopharma, and academic clients worldwide. Its portfolio spans Drug Project Toxicology, DMPK Project Support, specialist toxicology disciplines (inhalation, genetic, reproductive, immunotoxicology, medical devices), cardiac and CNS ion channel screening, in silico cardiac safety modelling, and AI-supported Target Safety Assessments. Services range from brief consultations to multi-year project support covering the full drug development lifecycle from target identification through regulatory submissions.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 4-day average turnaround for hERG screening data
+2 more records
Product overview1 text field

ApconiX is a nonclinical safety consultancy offering integrated toxicology, DMPK, ion channel screening, and safety science services. The portfolio comprises three interconnected service pillars: (1) Toxicology and DMPK Consultancy covering Drug Project Toxicology, DMPK Project Support, Toxicology Specialists, Study Monitoring, Due Diligence, and specialty services (Inhalation, Genetic, Reproductive, Safety Pharmacology, Immunotoxicology, Medical Devices, OELs/PDEs); (2) Ion Channel Screening encompassing Cardiac Liability (hERG/CiPA), CNS Liability (iLA panels), Additional Capabilities, and In Silico Cardiac Safety Modelling; and (3) Safety Science delivering Acuity Target Safety Assessments, Drug Safety, Data Science, and Weight of Evidence assessments. The company operates its own ion channel laboratory and has developed proprietary offerings including the iSLA in vitro Seizure Liability Assay.

Product and service20 records
1Drug Project Toxicology
CategoryToxicology and DMPK Consultancy
Description

Expert toxicology consultancy covering drug discovery and development phases including experimental strategy design, target safety assessments, GLP regulatory studies, and regulatory document authoring for IMPD, IB, CTA, and NDA/MAA/JNDA submissions.

2DMPK Project Support
CategoryToxicology and DMPK Consultancy
Description

Drug metabolism and pharmacokinetics consultancy supporting strategic DMPK approach implementation, compound optimization, dose prediction, PBPK/PKPD modeling, IVIVC, and clinical pharmacology support.

3Toxicology Specialists
CategoryToxicology and DMPK Consultancy
Description

World-leading toxicology expertise covering reproductive/paediatric, general, genetic, investigative toxicology, safety pharmacology, immunotoxicology, study monitoring, and PDE/OEL calculations.

4Nonclinical Study Monitoring
CategoryToxicology and DMPK Consultancy
Description

Independent study placement and monitoring service including CRO selection, study design input, oversight of in-life phases, and draft report review for scientific and regulatory rigor.

5Due Diligence
CategoryToxicology and DMPK Consultancy
Description

Expert technical appraisal of nonclinical safety and DMPK data for licensing deals, including critical review, data authenticity evaluation, and detailed risk reports.

6Inhalation Toxicology
CategorySpecialty Toxicology
Description

Specialist consultancy for inhaled therapies covering aerosol characterization, study design, CRO selection, and monitoring for First in Human through registration phases for small molecules and biologics.

7Genetic Toxicology
CategorySpecialty Toxicology
Description

Expert guidance on assessing DNA mutations and chromosomal damage from early screening through regulatory assays, including follow-on mechanistic studies and ICH/OECD guideline compliance.

8Reproductive Toxicology
CategorySpecialty Toxicology
Description

Specialist reproductive and developmental toxicology services including juvenile studies, Paediatric Investigation Plan (PIP) authoring, and regulatory agency interactions.

9Safety and Secondary Pharmacology
CategorySpecialty Toxicology
Description

Safety pharmacology study design and interpretation for core organ systems (cardiovascular, respiratory, CNS), plus in vitro secondary pharmacology screening for off-target activity identification.

10Immunotoxicology
CategorySpecialty Toxicology
Description

Assessment of immune system role in drug safety across small molecules, biologicals, and novel therapies, including immuno-oncology agents, immunogenicity, hypersensitivity reactions, and biomarker strategies.

11Medical Devices
CategorySpecialty Toxicology
Description

Biological and chemical safety testing guidance for medical device biocompatibility, including ISO 10993 series compliance, biological risk assessments, and toxicological risk assessments.

12OELs and PDEs
CategorySpecialty Toxicology
Description

Occupational Exposure Limit (OEL) and Permitted Daily Exposure (PDE) assessments written by expert toxicologists using NOAEL-based calculations per ICH and EMA guidelines.

13Cardiac Liability (hERG/CiPA)
CategoryIon Channel Screening
Description

Ion channel screening for cardiac safety including hERG screening, CiPA paradigm testing (hERG, hNav1.5, hCav1.2, hKir2.1, hKv4.3, hKvLQT1), and hiPSC-cardiomyocyte MEA assays using QPatch II, Patchliner, and Maestro Pro platforms.

14CNS Liability (iLA Panels)
CategoryIon Channel Screening
Description

In vitro CNS liability screening with a 15-ion channel panel (Nav1.1, Nav1.2, Nav1.6, Kv1.1, Kv2.1, Kv3.1, Kv4.2, Kv7.2/7.3, Kv7.3/7.5, KCa1.1, KCa4.1, Cav2.1, GABA α1β2γ2, NMDA 1/2A, Nicotinic α4β2, TREK1) and microelectrode array assay using human iPSC-derived neuronal co-cultures.

15Additional Ion Channel Capabilities
CategoryIon Channel Screening
Description

Manual patch-clamp services, recovery from block measurements for sodium channels with Vaughan-Williams classification, and sustainability initiatives including assay-ready cells and FBS reduction in cell culture.

16In Silico Cardiac Safety Modelling
CategoryIon Channel Screening
Description

Computational modeling service transforming ion channel IC50 data into mechanistic pro-arrhythmia risk assessments using O'Hara-Rudy human ventricular myocyte models to predict TdP risk including qNet and APD90 metrics, aligned with 2022 ICH E14/S7B Q&A guidelines.

17Acuity Target Safety Assessments (TSAs)
CategorySafety Science
Description

AI-supported toxicology reports analyzing target homology, gene/protein expression, transgenic and mutation phenotypes to identify key safety risks by organ/tissue, including embedded PowerPoint summaries.

18Data Science
CategorySafety Science
Description

Biodata analytics including safety informatics, predictive toxicology, chemoinformatics, target conservation and structural analysis, translational off-target safety, NGS data analysis, and systematic text mining.

19Weight of Evidence (WoE) Approach
CategorySafety Science
Description

Structured data integration service for science-based decisions including carcinogenicity assessment, DART WoE, and paediatric safety studies compliant with ICH guidelines.

20iSLA in vitro Seizure Liability Assay
CategoryIon Channel Screening
Description

Proprietary integrated in vitro screening approach for seizure liability assessment using microelectrode array (MEA) technology with human-derived neuronal stem cells and a 15-CNS-ion-channel panel, developed over three years and launched in July 2022.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeTechnology or Integration
Description

ApconiX uses Axion BioSystems' Maestro Pro MEA assay system for cardiotoxicity and seizure liability assays. The partnership enables investigation of potential cardiotoxicity in hiPSC-cardiomyocytes and CNS activity assessment using human iPSC-neuronal co-cultures.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

ApconiX has formed alliances with key international and global Contract Research Organisations (CROs) to provide comprehensive services on behalf of clients. They work with CROs for GLP toxicology studies, inhalation toxicology studies, and other specialized testing.

Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

An Evotec-owned contract research organization specializing in ADME/DMPK, in silico modeling, and in vitro safety pharmacology including cardiac (hERG) and CNS profiling. Highly comparable to Apconix's DMPK + ion channel screening offering and to Acuity TSAs.

TypeDirect peer
Description

UK-based preclinical contract research organization with a similar legacy AstraZeneca heritage and a broad nonclinical safety portfolio spanning general toxicology, safety pharmacology, reproductive toxicology, and genetic toxicology. Direct comparability comes from an overlapping service catalog and a comparable UK/European client base of biotech and biopharma sponsors.

TypeDirect peer
Description

UK-based drug discovery and nonclinical safety CRO offering integrated chemistry, biology, DMPK, and safety pharmacology services to biotech and pharma. Comparability flows from a similar UK footprint, integrated nonclinical offering, and primary customer base of small and mid-sized biotech.

TypeBroad incumbent
Description

Major CRO network providing nonclinical DMPK, safety pharmacology, and toxicology services globally. Overlaps with Apconix's screening and consultancy offerings but operates at a meaningfully larger scale, often as a competitor for outsourced nonclinical packages.

TypeBroad incumbent
Description

Global CRO with integrated drug discovery, DMPK, safety pharmacology, and toxicology capabilities. A broad incumbent competitor for integrated nonclinical safety work, particularly for biotech and larger pharma clients of Apconix.

TypeBroad incumbent
Description

One of the world's largest nonclinical and clinical CROs, providing full safety assessment, regulatory toxicology, and bioanalytical services. Comparable as the broad incumbent covering overlapping services (cardiac safety, DMPK, regulatory submissions) that biotech and large pharma may use as a substitute for Apconix.

TypeDirect peer
Description

Specialty contract research organization focused on cardiac safety (hERG, CiPA ion channels), target safety, and custom assay panels. Highly comparable to Apconix's ion channel screening and target safety assessment service lines with similar mid-sized CRO economics.

TypeDirect peer
Description

Preclinical CRO providing biosafety testing, cell line characterization, and viral clearance services. Comparable as a small-to-mid CRO in the nonclinical safety space serving biotech and gene therapy developers, with a similar boutique consulting-plus-lab-services model.

TypeDirect peer
Description

UK-based genetic toxicology and safety screening CRO with proprietary toxicology assays (e.g., GreenScreen HC, BlueScreen HC). Comparable because it serves the same biotech and large pharma safety assessment market with boutique specialty services from a similar UK base.

TypeBroad incumbent
Description

Global preclinical CRO with strong safety assessment, cardiovascular safety (hERG/CiPA), and ion channel services via the former Citoxlab. A broad incumbent with deep overlap to Apconix's cardiac and CNS liability offerings, serving the same biotech and biopharma customer base.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability6 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ApconiX

Nonclinical Drug Safety Consultingapconix.com

ApconiX is a UK-based nonclinical drug safety consultancy, founded in 2015, that delivers toxicology, DMPK, ion channel screening, and AI-supported target safety assessment services to biotech, biopharma, and academic clients across more than 30 countries.

What ApconiX does

ApconiX is a privately-held, UK-based nonclinical drug safety consultancy founded in July 2015 by Prof Ruth Roberts, Dr Richard Knight and Dr Michael Morton in the wake of AstraZeneca's closure of its Alderley Park R&D site. The firm is headquartered at Alderley Park (Cheshire) and operates a wholly-owned Swedish subsidiary, ApconiX AB, at the BioVentureHub in Gothenburg; it employs more than 100 scientists and markets over 500 years of combined drug discovery and development experience across all major safety disciplines.

The company is organised around three service pillars. Toxicology and DMPK Consultancy covers drug project toxicology, drug metabolism and pharmacokinetics, study monitoring, due diligence, inhalation toxicology, genetic and reproductive toxicology, safety and secondary pharmacology, immunotoxicology, medical device biocompatibility, and OEL/PDE calculations. Ion Channel Screening is delivered from the firm's own laboratory and includes cardiac safety assays (hERG and full CiPA panels on QPatch II, Patchliner, and Axion BioSystems Maestro Pro platforms), the proprietary iSLA in vitro Seizure Liability Assay, and in silico cardiac safety modelling aligned with ICH E14/S7B Q&A. Safety Science encompasses Acuity AI-supported Target Safety Assessments, weight-of-evidence evaluations, and data science services spanning predictive toxicology, chemoinformatics, and safety informatics.

ApconiX generates revenue through quote-based, project- and retainer-style professional services engagements ranging from short consulting hours to multi-year programme support. Customers are primarily small-to-mid-size biotechnology and large biopharmaceutical companies, with academia as a secondary segment, served through direct sales and CRO alliance channels; 60% of work is delivered to clients outside the UK across more than 30 countries. Named customers include Gilead Sciences, Sanofi and Bugworks Research, and the firm has received the Queen's Award for Enterprise for International Trade (2022), the King's Award for Enterprise for International Trade, and the King's Award for Enterprise for Innovation (2025), among other recognitions.

ApconiX firmographics

Firmographics
Name
ApconiX
Legal name
ApconiX Ltd.
Website
https://apconix.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
51–100 employees
Short description
ApconiX is a UK-based nonclinical drug safety consultancy, founded in 2015, that delivers toxicology, DMPK, ion channel screening, and AI-supported target safety assessment services to biotech, biopharma, and academic clients across more than 30 countries.
Ownership category
akta.pro rank

ApconiX industry classification

Industry
Product category
Nonclinical Drug Safety Consulting
NAICS
Testing Laboratories and Services (54138), Other Scientific and Technical Consulting Services (541690)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)
akta.pro industry
PRIMARYHLAGAAAC
Toxicology & Safety Assessment CROs (GLP)
SECONDARYHLAGAFAB
Safety Pharmacology (Cardio/CNS/Respiratory)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGAFAN
Nonclinical Study Management & Regulatory Writing (IND-enabling)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)

Keywords

  • Drug safety consulting
  • Nonclinical toxicology services
  • Ion channel screening
  • Target safety assessment
  • DMPK consultancy

Where ApconiX is headquartered

Location

Headquarters

HQ city
Macclesfield
HQ country
United Kingdom
HQ region
Europe

Offices2 records

Markets served

ApconiX business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Toxicology and DMPK Consultancy: Flexible consulting services providing access to experienced nonclinical safety scientists for drug discovery and development projects. Services include study design, CRO selection, study monitoring, regulatory document authoring, and expert toxicology advice. Works with discovery and development teams from project initiation through to worldwide marketing approval.
  2. Ion Channel Screening Services: Laboratory services for cardiac and CNS ion channel screening including hERG screening, CiPA assays, and seizure liability assessment. Turnaround times of 4 days for hERG and 14 days for CiPA screening.
  3. Safety Science and Target Safety Assessments: Acuity TSAs combining AI technology with expert toxicologist interpretation, Weight of Evidence assessments, and data science services for biodata analysis and predictive toxicology.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractProfessional consultancy services

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

ApconiX product offering

Product offering

Core offering

ApconiX provides expert nonclinical drug safety consultancy and laboratory-based ion channel screening services to biotech, biopharma, and academic clients worldwide. Its portfolio spans Drug Project Toxicology, DMPK Project Support, specialist toxicology disciplines (inhalation, genetic, reproductive, immunotoxicology, medical devices), cardiac and CNS ion channel screening, in silico cardiac safety modelling, and AI-supported Target Safety Assessments. Services range from brief consultations to multi-year project support covering the full drug development lifecycle from target identification through regulatory submissions.

Product overview

ApconiX is a nonclinical safety consultancy offering integrated toxicology, DMPK, ion channel screening, and safety science services. The portfolio comprises three interconnected service pillars: (1) Toxicology and DMPK Consultancy covering Drug Project Toxicology, DMPK Project Support, Toxicology Specialists, Study Monitoring, Due Diligence, and specialty services (Inhalation, Genetic, Reproductive, Safety Pharmacology, Immunotoxicology, Medical Devices, OELs/PDEs); (2) Ion Channel Screening encompassing Cardiac Liability (hERG/CiPA), CNS Liability (iLA panels), Additional Capabilities, and In Silico Cardiac Safety Modelling; and (3) Safety Science delivering Acuity Target Safety Assessments, Drug Safety, Data Science, and Weight of Evidence assessments. The company operates its own ion channel laboratory and has developed proprietary offerings including the iSLA in vitro Seizure Liability Assay.

Differentiator

Problem solved

Functional benefit

Brands

  • Acuity Target Safety Assessments (TSAs): AI-assisted target safety assessment products combining public domain information with expert toxicologist interpretation to identify key risks by organ/tissue.
  • iSLA
  • iSLA in vitro Seizure Liability Assay

Products and services

  • Drug Project Toxicology Expert toxicology consultancy covering drug discovery and development phases including experimental strategy design, target safety assessments, GLP regulatory studies, and regulatory document authoring for IMPD, IB, CTA, and NDA/MAA/JNDA submissions.
  • DMPK Project Support Drug metabolism and pharmacokinetics consultancy supporting strategic DMPK approach implementation, compound optimization, dose prediction, PBPK/PKPD modeling, IVIVC, and clinical pharmacology support.
  • Toxicology Specialists World-leading toxicology expertise covering reproductive/paediatric, general, genetic, investigative toxicology, safety pharmacology, immunotoxicology, study monitoring, and PDE/OEL calculations.
  • Nonclinical Study Monitoring Independent study placement and monitoring service including CRO selection, study design input, oversight of in-life phases, and draft report review for scientific and regulatory rigor.
  • Due Diligence Expert technical appraisal of nonclinical safety and DMPK data for licensing deals, including critical review, data authenticity evaluation, and detailed risk reports.
  • Inhalation Toxicology Specialist consultancy for inhaled therapies covering aerosol characterization, study design, CRO selection, and monitoring for First in Human through registration phases for small molecules and biologics.
  • Genetic Toxicology Expert guidance on assessing DNA mutations and chromosomal damage from early screening through regulatory assays, including follow-on mechanistic studies and ICH/OECD guideline compliance.
  • Reproductive Toxicology Specialist reproductive and developmental toxicology services including juvenile studies, Paediatric Investigation Plan (PIP) authoring, and regulatory agency interactions.
  • Safety and Secondary Pharmacology Safety pharmacology study design and interpretation for core organ systems (cardiovascular, respiratory, CNS), plus in vitro secondary pharmacology screening for off-target activity identification.
  • Immunotoxicology Assessment of immune system role in drug safety across small molecules, biologicals, and novel therapies, including immuno-oncology agents, immunogenicity, hypersensitivity reactions, and biomarker strategies.
  • Medical Devices Biological and chemical safety testing guidance for medical device biocompatibility, including ISO 10993 series compliance, biological risk assessments, and toxicological risk assessments.
  • OELs and PDEs Occupational Exposure Limit (OEL) and Permitted Daily Exposure (PDE) assessments written by expert toxicologists using NOAEL-based calculations per ICH and EMA guidelines.
  • Cardiac Liability (hERG/CiPA) Ion channel screening for cardiac safety including hERG screening, CiPA paradigm testing (hERG, hNav1.5, hCav1.2, hKir2.1, hKv4.3, hKvLQT1), and hiPSC-cardiomyocyte MEA assays using QPatch II, Patchliner, and Maestro Pro platforms.
  • CNS Liability (iLA Panels) In vitro CNS liability screening with a 15-ion channel panel (Nav1.1, Nav1.2, Nav1.6, Kv1.1, Kv2.1, Kv3.1, Kv4.2, Kv7.2/7.3, Kv7.3/7.5, KCa1.1, KCa4.1, Cav2.1, GABA α1β2γ2, NMDA 1/2A, Nicotinic α4β2, TREK1) and microelectrode array assay using human iPSC-derived neuronal co-cultures.
  • Additional Ion Channel Capabilities Manual patch-clamp services, recovery from block measurements for sodium channels with Vaughan-Williams classification, and sustainability initiatives including assay-ready cells and FBS reduction in cell culture.
  • In Silico Cardiac Safety Modelling Computational modeling service transforming ion channel IC50 data into mechanistic pro-arrhythmia risk assessments using O'Hara-Rudy human ventricular myocyte models to predict TdP risk including qNet and APD90 metrics, aligned with 2022 ICH E14/S7B Q&A guidelines.
  • Acuity Target Safety Assessments (TSAs) AI-supported toxicology reports analyzing target homology, gene/protein expression, transgenic and mutation phenotypes to identify key safety risks by organ/tissue, including embedded PowerPoint summaries.
  • Data Science Biodata analytics including safety informatics, predictive toxicology, chemoinformatics, target conservation and structural analysis, translational off-target safety, NGS data analysis, and systematic text mining.
  • Weight of Evidence (WoE) Approach Structured data integration service for science-based decisions including carcinogenicity assessment, DART WoE, and paediatric safety studies compliant with ICH guidelines.
  • iSLA in vitro Seizure Liability Assay Proprietary integrated in vitro screening approach for seizure liability assessment using microelectrode array (MEA) technology with human-derived neuronal stem cells and a 15-CNS-ion-channel panel, developed over three years and launched in July 2022.

Quantifiable outcome

  • 4-day average turnaround for hERG screening data
  • +2 more outcomes

Companies that use ApconiX

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles2 records

ApconiX technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature5 records

ApconiX partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Axion BioSystemscoreTechnology or IntegrationApconiX uses Axion BioSystems' Maestro Pro MEA assay system for cardiotoxicity and seizure liability assays. The partnership enables investigation of potential cardiotoxicity in hiPSC-cardiomyocytes and CNS activity assessment using human iPSC-neuronal co-cultures.
  • Key International CROscoreChannel Partner/ Reseller/ DistributorApconiX has formed alliances with key international and global Contract Research Organisations (CROs) to provide comprehensive services on behalf of clients. They work with CROs for GLP toxicology studies, inhalation toxicology studies, and other specialized testing.

Scale indicators6 records

Recent moves10 records

Expansion highlights5 records

ApconiX competitors and assessment

Company assessment

Direct peers

  • Cyprotex (Evotec): An Evotec-owned contract research organization specializing in ADME/DMPK, in silico modeling, and in vitro safety pharmacology including cardiac (hERG) and CNS profiling. Highly comparable to Apconix's DMPK + ion channel screening offering and to Acuity TSAs.
  • Sequani: UK-based preclinical contract research organization with a similar legacy AstraZeneca heritage and a broad nonclinical safety portfolio spanning general toxicology, safety pharmacology, reproductive toxicology, and genetic toxicology. Direct comparability comes from an overlapping service catalog and a comparable UK/European client base of biotech and biopharma sponsors.
  • Concept Life Sciences: UK-based drug discovery and nonclinical safety CRO offering integrated chemistry, biology, DMPK, and safety pharmacology services to biotech and pharma. Comparability flows from a similar UK footprint, integrated nonclinical offering, and primary customer base of small and mid-sized biotech.
  • Reaction Biology Corp. Specialty contract research organization focused on cardiac safety (hERG, CiPA ion channels), target safety, and custom assay panels. Highly comparable to Apconix's ion channel screening and target safety assessment service lines with similar mid-sized CRO economics.
  • Bionova Scientific: Preclinical CRO providing biosafety testing, cell line characterization, and viral clearance services. Comparable as a small-to-mid CRO in the nonclinical safety space serving biotech and gene therapy developers, with a similar boutique consulting-plus-lab-services model.
  • Gentronix Limited: UK-based genetic toxicology and safety screening CRO with proprietary toxicology assays (e.g., GreenScreen HC, BlueScreen HC). Comparable because it serves the same biotech and large pharma safety assessment market with boutique specialty services from a similar UK base.

Broad incumbents

  • Eurofins Discovery: Major CRO network providing nonclinical DMPK, safety pharmacology, and toxicology services globally. Overlaps with Apconix's screening and consultancy offerings but operates at a meaningfully larger scale, often as a competitor for outsourced nonclinical packages.
  • Pharmaron: Global CRO with integrated drug discovery, DMPK, safety pharmacology, and toxicology capabilities. A broad incumbent competitor for integrated nonclinical safety work, particularly for biotech and larger pharma clients of Apconix.
  • Labcorp Drug Development (Covance): One of the world's largest nonclinical and clinical CROs, providing full safety assessment, regulatory toxicology, and bioanalytical services. Comparable as the broad incumbent covering overlapping services (cardiac safety, DMPK, regulatory submissions) that biotech and large pharma may use as a substitute for Apconix.
  • Charles River Laboratories: Global preclinical CRO with strong safety assessment, cardiovascular safety (hERG/CiPA), and ion channel services via the former Citoxlab. A broad incumbent with deep overlap to Apconix's cardiac and CNS liability offerings, serving the same biotech and biopharma customer base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

ApconiX social profiles

Digital presence

ApconiX financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ApconiX leadership team

Management profile

Number of profiles

Profiles10 records

ApconiX subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

ApconiX funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ApconiX M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ApconiX

What does ApconiX do?

ApconiX provides expert nonclinical drug safety consultancy and laboratory-based ion channel screening services to biotech, biopharma, and academic clients worldwide. Its portfolio spans Drug Project Toxicology, DMPK Project Support, specialist toxicology disciplines (inhalation, genetic, reproductive, immunotoxicology, medical devices), cardiac and CNS ion channel screening, in silico cardiac safety modelling, and AI-supported Target Safety Assessments. Services range from brief consultations to multi-year project support covering the full drug development lifecycle from target identification through regulatory submissions.

Is ApconiX a public or private company?

ApconiX is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was ApconiX founded?

ApconiX was founded in 2015. It employs 51 to 100 people.

Where is ApconiX based?

ApconiX is headquartered in Macclesfield, United Kingdom, in the Europe region.

How does ApconiX make money?

Three revenue lines are on record. Toxicology and DMPK Consultancy is the primary driver. The others are ion Channel Screening Services and safety Science and Target Safety Assessments.

Who are ApconiX's main competitors?

Direct peers on record are Cyprotex (Evotec), Sequani, Concept Life Sciences, Reaction Biology Corp., Bionova Scientific and Gentronix Limited. Broad incumbents are Eurofins Discovery, Pharmaron, Labcorp Drug Development (Covance) and Charles River Laboratories.

Does ApconiX have an API?

No public API is recorded for ApconiX.

What industry is ApconiX in?

ApconiX's product category is Nonclinical Drug Safety Consulting. Its primary akta.pro industry code is HLAGAAAC, Toxicology & Safety Assessment CROs (GLP), with a secondary code of HLAGAFAB, Safety Pharmacology (Cardio/CNS/Respiratory). Its NAICS code is 54138 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales